Scholar Rock Holding Corporation

Scholar Rock is a biotechnology company developing drugs for rare neuromuscular diseases like spinal muscular atrophy and muscular dystrophy, as well as certain cancers and blood disorders. The company's approach focuses on blocking proteins called growth factors that contribute to these diseases. Their most advanced drug candidate, Apitegromab, is currently being tested in patients with spinal muscular atrophy and another muscle disease called facioscapulohumeral muscular dystrophy. They have several other experimental drugs in earlier stages of testing for muscle diseases, resistant cancers,...